Search is Powered by Google
HIV / AIDS News

Gannett Desert Sun Examines Antiretroviral Isentress

Main Category: HIV / AIDS
Article Date: 20 Nov 2008 - 9:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Gannett/Desert Sun on Monday examined Merck's antiretroviral drug Isentress, which was approved by FDA last year. According to Gannett/Desert Sun, since FDA approved the drug, some HIV-positive people and "medical experts say it appears to work, improving the condition of some HIV patients and sparking hope that drugmakers may develop similar medications."

Isentress, which is known generically as raltegravir, has been shown to be effective for people who have developed resistance to other available drugs. The medication is part of a new class of drugs called integrase inhibitors. Homayoon Khanlou, chief of medicine for the AIDS Healthcare Foundation, said, "We do need the new class of drugs. There are not many newer agents in the pipeline." Roy Steigbigel -- a professor of medicine at Stony Brook University in New York who recently co-authored a study on Isentress in the New England Journal of Medicine -- said the drug shows "great promise in people whose virus is resistant to many of the other available drugs." He also said studies are "ongoing" to determine if similar results would be seen in patients who have never taken antiretrovirals.

According to Gannett/Sun, Isentress was approved in six months under an FDA fast-track process, which some advocates and lawmakers say they would like the agency to use more frequently to increase approval of HIV/AIDS drugs. Mark Milano, an HIV treatment educator at the AIDS Community Research Initiative of America, said, "People are dying now. If we wait five more years to get the drugs out, people will avoid the risks but they will also be dead." Gannett/Sun reports that the Desert AIDS Project for six months last year participated in a clinical trial of Isentress, during which participants were offered the new drug along with other medications (Barfield Berry, Gannett/Desert Sun, 11/17).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

View drug information on Isentress.





Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Increase In Anal Intercourse Involving At-Risk Teens And Young Adults
22 Nov 2008
A new study by researchers at the Bradley Hasbro Children's Research Center suggests that the incidence of heterosexual anal sex is increasing among teens and young adults - particularly those who have recently had unprotected vaginal sex...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

Keeping a Personal Medical Record image Keeping a Personal Medical Record

Medical information is usually scattered in many different places. To receive the best possible health care, people are encouraged to gather information in one place and create a personal medical record...

View more videos...